Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 13/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16834202 | 0.82 | ALDH1A1 (0.34) | ALDH1A1NPSR1MAPTPOLBHTT | |
| SCHEMBL17459753 | 0.80 | ALDH1A1 (0.33) | ALDH1A1NPSR1MAPTPOLBHTT | |
| SCHEMBL3399592 | 0.79 | CRHR1 (0.34) | ALDH1A1NPSR1MAPTPOLBHTT | |
| SCHEMBL16834246 | 0.77 | ALDH1A1 (0.37) | ALDH1A1NPSR1MAPTPOLBHTT | |
| Hydrochloric Acid SCHEMBL2796752 | 0.76 | ALDH1A1 (0.36) | ALDH1A1NPSR1MAPTPOLBHTT | |
| Hydrochloric Acid SCHEMBL2796754 | 0.76 | ALDH1A1 (0.36) | ALDH1A1NPSR1MAPTPOLBHTT | |
| SCHEMBL4222761 | 0.74 | ALDH1A1 (0.35) | ALDH1A1NPSR1MAPTPOLBHTT | |
| SCHEMBL4219437 | 0.74 | ALDH1A1 (0.35) | ALDH1A1NPSR1MAPTPOLBHTT | |
| SCHEMBL4227079 | 0.74 | ALDH1A1 (0.35) | ALDH1A1NPSR1MAPTPOLBHTT | |
| SCHEMBL1662433 | 0.72 | ALDH1A1 (0.34) | ALDH1A1NPSR1MAPTPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117916227-A | Process for preparing perfuming intermediates | 弗门尼舍有限公司 | 2024-04-19 | — | — | CN | claimed |
| WO-2023109506-A1 | POLYMERIC STERICALLY HINDERED AMINE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 天集化工助剂（沧州）有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-11332426-B2 | Method of preparing trisubstituted ethylene compounds | TRUSTEES OF BOSTON COLLEGE (US) | 2022-05-17 | — | — | US | disclosed |
| CN-107922426-B | Tetrahydrooxepin pyridine compound | 安斯泰来制药株式会社 | 2021-03-26 | — | — | CN | disclosed |
| CN-112218864-A | N-1 branched cycloalkyl substituted imidazo [4,5-c ] quinoline compounds, compositions, and methods | 3M创新有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-20190352312-A1 | PYRIDYL-TRIAZABICYCLES | HOFFMANN-LA ROCHE INC. | 2019-11-21 | — | — | US | disclosed |
| EP-1301458-B1 | SYNTHESIS OF FUNCTIONALIZED AND UNFUNCTIONALIZED OLEFINS VIA CROSS AND RING-CLOSING METATHESIS | CALIFORNIA INST OF TECHN (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-1301458-A4 | SYNTHESIS OF FUNCTIONALIZED AND UNFUNCTIONALIZED OLEFINS VIA CROSS AND RING-CLOSING METATHESIS | CALIFORNIA INST OF TECHN (US) | 2006-11-02 | — | — | EP | disclosed |
| US-6794534-B2 | USING AS CATALYST RUTHENIUM OR OSMIUM CARBENE COMPLEXES CONTAINING AN IMIDAZOLIDINE LIGAND | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2004-09-21 | — | — | US | disclosed |
| EP-1301458-A1 | SYNTHESIS OF FUNCTIONALIZED AND UNFUNCTIONALIZED OLEFINS VIA CROSS AND RING-CLOSING METATHESIS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20020137978-A1 | Synthesis of functionalized and unfunctionalized olefins via cross and ring-closing Metathesis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-26 | — | — | US | disclosed |
| WO-2002000590-A1 | SYNTHESIS OF FUNCTIONALIZED AND UNFUNCTIONALIZED OLEFINS VIA CROSS AND RING-CLOSING METATHESIS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352312-A1 | PYRIDYL-TRIAZABICYCLES | BACE1, BACE2, PSEN1 | ALDH1A1 367/4885NPSR1 1868/4885MAPT 17/4885 |
| US-11332426-B2 | Method of preparing trisubstituted ethylene compounds | EMC1, EMC2, ESR1 | ALDH1A1 3441/4885NPSR1 2705/4885MAPT 2784/4885 |
| US-20020137978-A1 | Synthesis of functionalized and unfunctionalized olefins via cross and ring-closing Metathesis | OXER1, AOC2, CBR1 | ALDH1A1 388/4885NPSR1 3509/4885MAPT 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.